The One FDA Request You Cannot Refuse

Most FDA warning letters are about quality systems. Missing investigations. Inadequate CAPA closure. Stability programs that exist on paper and fail under scrutiny. The May 22, 2026 warning letter to Aeroflex Industria de Aerosol Ltda, a Brazilian manufacturer of OTC drug products, is about something more basic than any of that. Corporate management said no to the FDA.

That is not a legal position. It is not a negotiable posture. It is a warning letter.

Under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act, FDA has statutory authority to copy and verify records during an inspection. This is not a request the agency makes as a courtesy. It is an obligation that attaches the moment a manufacturer produces drug products intended to enter US commerce. Aeroflex makes OTC drug products in pressurized aerosol containers, sprays and foams, and markets them in the United States. That is enough. The obligation applies regardless of where the facility sits or which country issued its operating license.

When corporate management refused to provide the records FDA requested, the agency cited the refusal as a violation and issued a warning letter. The immediate enforcement consequence is this: FDA cannot determine whether CGMP violations exist at the facility because it could not access the records that would allow it to make that determination. The firm has answered the compliance question with a closed door, and FDA treats a closed door as a negative finding.

There are two explanations for why a firm refuses FDA records access. The first is that management had something to hide and calculated that refusal was preferable to disclosure. The second is that management genuinely did not understand the scope of FDA authority under 704(a)(4) and believed refusal was a legitimate option. Both explanations produce identical enforcement outcomes. The warning letter exists. The compliance question remains open. And the remediation burden is now significantly larger than whatever the underlying inspection was trying to assess.

Quality professionals who work with foreign manufacturers, whether as US agents, contract auditors, or supply chain partners, should read this case carefully. FDA jurisdiction does not terminate at the US border. It applies to any facility that manufactures, processes, or holds drug products intended for the US market. Aeroflex is a Brazilian company. The warning letter found it anyway.

The practical implication for quality teams is not complicated. When FDA requests records under 704(a)(4), the answer is not no. It is not no after consulting legal. It is not no pending translation review. The statutory obligation to provide access exists, and the moment corporate leadership refuses, the firm has created a new and unambiguous enforcement finding layered on top of whatever the original inspection was examining.

There is also a credibility cost that compounds from there. Because FDA could not access Aeroflex's records, the agency cannot determine whether CGMP violations exist. That uncertainty does not resolve in the firm's favor. FDA's working assumption when records are withheld is that the records would confirm the problems the inspection was already probing. The firm has traded an unknown compliance risk for a confirmed enforcement action, and still has not answered the original question. The debt doubled.

For quality directors preparing sites for FDA inspection, the Aeroflex case is a useful reminder that inspection readiness is not only about what your batch records, deviation logs, and CAPA documentation show. It is also about ensuring that corporate leadership understands what they are legally required to provide when FDA arrives and makes a formal records request. A quality system that holds up under paper review but collapses when management makes a poor call in the moment is not inspection-ready. It is fragile in exactly the way regulators test for.

FDA's 704(a)(4) authority has been on the books for decades. Most facilities never encounter it in a warning letter because most facilities do not refuse to cooperate. Aeroflex is now the documented case study for why that cooperation is not optional. The lesson is simple. The consequences for missing it are not.